Good call overall. I still think NP gives the E
Post# of 145655
![](/assets/46931549/no_avatar_available_thumb.jpg)
I still think NP gives the EFF-DA too much credit. If the EFF-DA was so keen on fast-tracking leronlimab by granting ph2 and ph3 trials, then WTF are they now sputtering to give EUA after a gold-standard, double-blind, accept every applicant without exception, no-one-wants-to-touch m2m group, with statistical significance proving efficacy? Is it that they think its too good to be true?
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)